Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Dec 21;13:1052060. doi: 10.3389/fphar.2022.1052060

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Giudice, Serio, Ferrara, Manzo, Gorrese, Pepe, Bertolini, D’Alto, Verdesca, Langella, Filippelli and Selleri.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Clinical outcomes of patients treated with azacytidine plus venetoclax (A) overall survival (OS) and (B) progression-free survival (PFS) are reported for patients treated with azacytidine plus venetoclax (aza-venetoclax cohort) or to azacytidine as single agent (historical cohort), divided by diagnosis [low-risk myelodysplastic syndrome (MDS), MDS with excess of blast (EB) of type 1 and 2, and acute myeloid leukemia (AML)] (C) OS e (D) PFS are also shown for patients of the aza-venetoclax cohort treated with the drug combination as upfront therapy, or as a second or more line treatment. A p < 0.05 was considered statistically significant.